Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone415-374-7782
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$68.22 million
Profitability
Miscellaneous
Employees594
OptionableOptionable
InVitae (NYSE:NVTA) Frequently Asked Questions
What is InVitae's stock symbol?
InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were InVitae's earnings last quarter?
InVitae Corp (NYSE:NVTA) announced its quarterly earnings results on Wednesday, November, 7th. The medical research company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.02. The medical research company earned $37.37 million during the quarter, compared to analyst estimates of $34.80 million. InVitae had a negative return on equity of 103.37% and a negative net margin of 109.60%. The firm's revenue was up 105.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.57) earnings per share. View InVitae's Earnings History.
When is InVitae's next earnings date?
What guidance has InVitae issued on next quarter's earnings?
InVitae issued an update on its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $220-220 million, compared to the consensus revenue estimate of $200 million.InVitae also updated its FY 2018 guidance to EPS.
What price target have analysts set for NVTA?
5 analysts have issued 1-year target prices for InVitae's stock. Their forecasts range from $16.00 to $20.00. On average, they expect InVitae's share price to reach $17.6667 in the next twelve months. This suggests a possible upside of 18.3% from the stock's current price. View Analyst Price Targets for InVitae.
What is the consensus analysts' recommendation for InVitae?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae.
Has InVitae been receiving favorable news coverage?
Press coverage about NVTA stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. InVitae earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near future.
Are investors shorting InVitae?
InVitae saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 5,469,462 shares, an increase of 67.9% from the December 14th total of 3,257,607 shares. Based on an average trading volume of 1,257,227 shares, the short-interest ratio is presently 4.4 days. Currently, 7.9% of the company's shares are sold short. View InVitae's Current Options Chain.
Who are some of InVitae's key competitors?
Some companies that are related to InVitae include Guardant Health (GH), Genomic Health (GHDX), CareDx (CDNA), Natera (NTRA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), Fulgent Genetics (FLGT), PotNetwork (POTN), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and CBA Florida (CBAI).
Who are InVitae's key executives?
InVitae's management team includes the folowing people:
- Dr. Randal W. Scott, Exec. Chairman (Age 60)
- Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 44)
- Ms. Shelly D. Guyer, Chief Financial Officer (Age 58)
- Mr. Lee Bendekgey, Chief Operating Officer (Age 60)
- Ms. Laura D'Angelo, Head of Investor Relations
When did InVitae IPO?
(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Who are InVitae's major shareholders?
InVitae's stock is owned by a number of of retail and institutional investors. Top institutional investors include Daiwa SB Investments Ltd. (0.43%), Boston Advisors LLC (0.07%) and Meeder Asset Management Inc. (0.02%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae.
Which institutional investors are buying InVitae stock?
NVTA stock was bought by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd., Meeder Asset Management Inc. and Boston Advisors LLC. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker and Randal W Scott. View Insider Buying and Selling for InVitae.
How do I buy shares of InVitae?
Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InVitae's stock price today?
One share of NVTA stock can currently be purchased for approximately $14.94.
How big of a company is InVitae?
InVitae has a market capitalization of $1.07 billion and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. InVitae employs 594 workers across the globe.
What is InVitae's official website?
How can I contact InVitae?
InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for InVitae (NYSE NVTA)
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
